Thomas Shannon
Angel Investor
Saukville, United States
Thomas Shannon is a seed investor in Saukville focused on Medical and SaaS. Tom Shannon is President and CEO of BrightStar. He was board chairman and a lead investor in Proxim Diagnostics Corp., Somna Therapeutics LLC, and Aver Informatics Inc. and CEO of biotech company Prodesse Inc. Tom has also served as a director of the Wisconsin Angel Network, Promentis Pharmaceuticals Inc., Stemina Biomarker Discovery Inc. andOKANJO Partners Inc. He has earned the CFP credentials and is an inductee into the Wisconsin Investor hall of fame.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Thomas Shannon invests in
Stages Thomas Shannon invests in
Countries Thomas Shannon invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (50%)
- SaaS 1 (25%)
- Audio 1 (25%)
- Energy 1 (25%)
- Big Data 1 (25%)
Stage
- Seed 2 (50%)
- Angel 1 (25%)
- Series B 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Founded in March 2012 in partnership with the Medical College of Wisconsin, Somna Therapeutics is a medical device company focused on improving the quality of life for the millions of people suffering from laryngopharyngeal reflux (LPR) / extraesophageal acid reflux disease (EERD). The Reza Band™, UES Assist Device is designed to be anon-invasive solution. In the near-term, Somna Therapeutics is planning to optimize product design and complete clinical trials to gain FDA clearance. We anticipate upon FDA clearance and product launch, to be selling to hospitals, physician clinics, and home health care. | $1.2M / Seed / May 02, 2012 | ||
| HarQen unleashes the richness of information trapped inside conversations — transforming voice into actionable insights. Founded in 2007, HarQen's award-winning Intelligent Voice Services enables meetings, interviews and other conversations to be captured, enriched and shared, improving collaboration and productivity. HarQen is also afounding member of the Hypervoice Consortium. Hypervoice is an emerging model for organizing and navigating voice conversations. The technology within Symposia, HarQen's second application, showcases the first example of Hypervoice capabilities for use in enterprise social collaboration. | $4.3M / Series B / Oct 13, 2011 | ||
| Shamrock Energy uses nanomaterials to develop better ways to store and use energy. The company is headquartered in Oshkosh, Wisconsin, United States. | $580K / Angel / Feb 08, 2011 | ||
| Prodesse develops molecular diagnostic reagents for a variety of infectious disease applications. Prodesse sells three FDA 510(k) cleared products in the United States, and two additional CE-marked products in Europe. The company's products can be used in conjunction with various nucleic acid extraction and real-time PCR (polymerase chainreaction) platforms, including Cepheid's SmartCycler(®) II System. | $1.5M / Seed / Jan 01, 2002 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Thomas Shannon invest in?
Thomas Shannon invests primarily in Medical, SaaS and Audio startups, most often at Seed and Angel stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Thomas Shannon?
Public channels for Thomas Shannon include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Thomas Shannon last invest?
The most recent investment recorded for Thomas Shannon closed in May 2012. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
